Table 3 The main PK parameters in NSCLC patients after a single oral dose of MET306 tablets at different doses
Dose group (mg) | n | Cmax (ng mL−1) | Tmax (h) | T1/2 (h) | AUC0−t (ng h mL−1) | AUC0−∞ (ng h mL−1) | VD/F (L) | CL/F (L h−1) |
|---|---|---|---|---|---|---|---|---|
10 | 1 | 14.6 | 5 | 21.8 | 268 | 296 | 1062 | 33.8 |
20 | 3 | 24.4 ± 7.97 | 5.00 ± 0.00 | 20.9 ± 2.02 | 535 ± 228 | 564 ± 236 | 1181 ± 403 | 40.2 ± 17.5 |
30 | 3 | 30.2 ± 8.72 | 5.34 ± 0.00 | 20.8 ± 3.64 | 838 ± 509 | 891 ± 553 | 1251 ± 603 | 45.0 ± 29.3 |
45 | 3 | 49.2 ± 13.3 | 4.33 ± 1.53 | 21.7 ± 0.28 | 1181 ± 359 | 1229 ± 372 | 1211 ± 322 | 38.8 ± 10.7 |
60 | 4 | 58.0 ± 33.5 | 4.50 ± 2.39 | 25.9 ± 6.78 | 1327 ± 693 | 1452 ± 808 | 1856 ± 847 | 55.3 ± 37.3 |
80 | 4 | 95.6 ± 28.3 | 4.50 ± 1.73 | 22.2 ± 3.1 | 2142 ± 695 | 2249 ± 760 | 1218 ± 340 | 39.12 ± 14.62 |
105 | 5 | 144.3 ± 84.7 | 4.40 ± 2.51 | 20.40 ± 3.17 | 2994 ± 2040 | 3323 ± 1890 | 1192 ± 619 | 41.80 ± 25.11 |
140 | 1 | 131.1 | 3 | 19.63 | 2582 | 2662 | 1490 | 52.6 |